Key facts
- It has raised $324.2M; the latest was Mezzanine ($20.1M) in Mar 2025.
- Notable investors include ARCH Venture Partners, Baillie Gifford, Alpha Wave Global, Polaris Partners, The Invus Group — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for KSQ
- ·The full record, as it builds
Funding rounds
No funding rounds for KSQ are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KSQ
Developer of transformative medicines designed to systematically pinpoint the optimal nodal targets of disease with precision. The company's industrialized functional genomics engine utilizes a suite of tools that identify novel pathways and targets involved in oncology and immuno-oncology, enabling doctors to uncover novel drug targets, and mechanisms for drug efficacy and identify transformative single-agent and combination therapies to benefit patients.
- Sector
- Healthcare
- HQ
- Lexington, MA, United States
- Founded
- 2015
- Employees
- 103
- Website
- ksqtx.com/
- Ownership
- Privately Held (backing)
KSQ doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KSQ shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KSQ in its N-PORT filings yet. We sweep new filings monthly.